CETROTIDE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Cetrotide, and what generic alternatives are available?
Cetrotide is a drug marketed by Emd Serono Inc and is included in one NDA.
The generic ingredient in CETROTIDE is cetrorelix acetate. There is one drug master file entry for this compound. Six suppliers are listed for this compound. Additional details are available on the cetrorelix acetate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Cetrotide
A generic version of CETROTIDE was approved as cetrorelix acetate by TEVA PHARMS INC on August 12th, 2022.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for CETROTIDE?
- What are the global sales for CETROTIDE?
- What is Average Wholesale Price for CETROTIDE?
Summary for CETROTIDE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 41 |
| Clinical Trials: | 59 |
| Patent Applications: | 7,592 |
| Drug Prices: | Drug price information for CETROTIDE |
| What excipients (inactive ingredients) are in CETROTIDE? | CETROTIDE excipients list |
| DailyMed Link: | CETROTIDE at DailyMed |
Recent Clinical Trials for CETROTIDE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Trust Fertility Clinic | PHASE4 |
| Beni-Suef University | PHASE3 |
| Mỹ Đức Hospital | NA |
US Patents and Regulatory Information for CETROTIDE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Emd Serono Inc | CETROTIDE | cetrorelix acetate | POWDER;SUBCUTANEOUS | 021197-001 | Aug 11, 2000 | AP | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Emd Serono Inc | CETROTIDE | cetrorelix acetate | POWDER;SUBCUTANEOUS | 021197-002 | Aug 11, 2000 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for CETROTIDE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Emd Serono Inc | CETROTIDE | cetrorelix acetate | POWDER;SUBCUTANEOUS | 021197-002 | Aug 11, 2000 | 4,800,191 | ⤷ Start Trial |
| Emd Serono Inc | CETROTIDE | cetrorelix acetate | POWDER;SUBCUTANEOUS | 021197-001 | Aug 11, 2000 | 4,800,191 | ⤷ Start Trial |
| Emd Serono Inc | CETROTIDE | cetrorelix acetate | POWDER;SUBCUTANEOUS | 021197-001 | Aug 11, 2000 | 6,319,192 | ⤷ Start Trial |
| Emd Serono Inc | CETROTIDE | cetrorelix acetate | POWDER;SUBCUTANEOUS | 021197-001 | Aug 11, 2000 | 7,605,121 | ⤷ Start Trial |
| Emd Serono Inc | CETROTIDE | cetrorelix acetate | POWDER;SUBCUTANEOUS | 021197-002 | Aug 11, 2000 | 7,605,121 | ⤷ Start Trial |
| Emd Serono Inc | CETROTIDE | cetrorelix acetate | POWDER;SUBCUTANEOUS | 021197-001 | Aug 11, 2000 | 6,863,891 | ⤷ Start Trial |
| Emd Serono Inc | CETROTIDE | cetrorelix acetate | POWDER;SUBCUTANEOUS | 021197-002 | Aug 11, 2000 | 5,198,533 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
EU/EMA Drug Approvals for CETROTIDE
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| Merck Europe B.V. | Cetrotide | cetrorelix | EMEA/H/C/000233Prevention of premature ovulation in patients undergoing a controlled ovarian stimulation, followed by oocyte-pick-up and assisted-reproductive techniques.In clinical trials, Cetrotide was used with human menopausal gonadotropin (HMG), however, limited experience with recombinant follicule-stimulating hormone (FSH) suggested similar efficacy. | Authorised | no | no | no | 1999-04-12 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for CETROTIDE
See the table below for patents covering CETROTIDE around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Austria | 90362 | ⤷ Start Trial | |
| Brazil | 1100478 | ⤷ Start Trial | |
| Canada | 1339623 | ANTAGONISTE DE LA LUBERINE (LHRH ANTAGONISTS) | ⤷ Start Trial |
| Germany | 19975052 | ⤷ Start Trial | |
| Germany | 3823590 | ⤷ Start Trial | |
| Germany | 3881592 | ⤷ Start Trial | |
| Denmark | 173375 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for CETROTIDE
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0299402 | C990029 | Netherlands | ⤷ Start Trial | PRODUCT NAME: CETRORELIX, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAAR DBAAR ZUUR ADDITIEZOUT, IN HET BIJZONDER CETRORELIX ACETAAT; REGISTRATION NO/DATE: EU/1/99/100/001-003 19990413 |
| 0299402 | 099C0031 | Belgium | ⤷ Start Trial | PRODUCT NAME: ACETATE DE CETRORELIX; REGISTRATION NO/DATE: EU/1/99/100/001 19990413 |
| 0299402 | 31/1999 | Austria | ⤷ Start Trial | PRODUCT NAME: CETRORELIX UND PHARMAZEUTISCH ANNEHMBARE SAEUREADDITIONSSALZE DAVON, INSBESONDERE CETRORELIXACETAT; REGISTRATION NO/DATE: EU/1/99/100/001- EU/1/99/100/003 19990413 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
More… ↓
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch